免疫细胞疗法在IBD治疗中的研究进展  

Progress of immunocellular therapy in treatment of IBD

作　　者：周建伟 张哲 刘霞[1] 孙亚星 王亮 冯百岁[1] ZHOU Jianwei;ZHANG Zhe;LIU Xia;SUN Yaxing;WANG Liang;FENG Baisui(Department of Gastroenterology,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China)

机构地区：[1]郑州大学第二附属医院消化内科,郑州450014

出　　处：《中国免疫学杂志》2024年第6期1324-1328,共5页Chinese Journal of Immunology

基　　金：河南省重点研发与推广专项(科技攻关)(212102310803);2021年度河南省医学科技攻关计划联合共建项目(LHGJ20210409,LHGJ20210424,LHGJ20210416)。

摘　　要：炎症性肠病(IBD)是一种以慢性、复发性肠道炎症为特征的疾病,包括克罗恩病(CD)和溃疡性结肠炎(UC)。其病因和发病机制仍然不明,难以治愈。近年来,以调节性T(Treg)细胞疗法和树突状细胞(DC)疗法为代表的免疫细胞疗法在免疫相关疾病治疗领域发展十分迅速,在IBD治疗领域也取得了一定进展。本文主要介绍Treg细胞疗法和DC疗法在IBD治疗中的应用及进展。Inflammatory bowel disease(IBD)is a disease characterized by chronic,recurrent intestinal inflammation,includ-ing Crohn's disease(CD)and ulcerative colitis(UC).Etiology and pathogenesis of IBD are unknown,and the treatment is difficult.In recent years,immunocellular therapy represented by regulatory T(Treg)cell therapy and dendritic cell(DC)therapy has developed rapidly in the field of immune-related disease treatment,and some progress has also been made in the treatment of IBD.This review will introduce application and progression of Treg cell therapy and DC therapy in IBD treatment.

关 键 词：炎症性肠病 免疫细胞疗法 调节性T细胞 树突状细胞 

分 类 号：R392[医药卫生—免疫学]